In November 2025, Iovance reported that clinical results for IOV-4001, a PD-1 inactivated TIL cell therapy, in previously treated advanced melanoma patients are anticipated in the first quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback